Recent Supreme Court rulings have fundamentally transformed how mass tort claims are handled in bankruptcy court, restricting the tools that large corporations once used to shield themselves and their executives from liability. The watershed moment came on June 27, 2024, when the U.S. Supreme Court ruled 5-4 in *Harrington v. Purdue Pharma* that the Bankruptcy Code does not permit Chapter 11 reorganization plans to discharge claims against non-debtors without their explicit consent—a decision that cut off the primary mechanism used in the opioid crisis bankruptcies.
This ruling has forced bankruptcy courts, legislators, and claimants’ attorneys to reimagine how mass tort settlements will be structured going forward, shifting emphasis away from corporate bankruptcy filings as a defensive shelter and toward class actions, multi-district litigation, and negotiated settlements that actually require the consent of affected parties. The implications have been swift and visible. The revised *Purdue Pharma* plan approved in late 2025 reflected these new constraints, securing approximately $7 billion in contributions from the Sackler family while significantly narrowing the protections given to non-debtors—a stark reversal from the original plan’s broad third-party releases. At the same time, other solvent companies have learned that attempting to use bankruptcy as a defensive tactic no longer works: when Johnson & Johnson filed its third talc-related bankruptcy in 2025, a bankruptcy court dismissed it outright. Taken together, these rulings are reshaping the mass tort landscape by making bankruptcy a less attractive option for defendants and a more transparent, consensual process for claimants.
Table of Contents
- How Have Supreme Court Rulings Limited Bankruptcy Protections for Corporations?
- What Happens When Solvent Companies Try to Use Bankruptcy as a Defensive Shield?
- What New Mass Torts Are Emerging in 2026?
- How Are Courts Redirecting Mass Tort Claims Away from Bankruptcy?
- What Legislative Reforms Are Anticipated?
- How Did the Bad Faith Ruling of June 2026 Further Restrict Bankruptcy Plans?
- What Does the Purdue Pharma Template Mean for Future Mass Tort Bankruptcies?
- Frequently Asked Questions
How Have Supreme Court Rulings Limited Bankruptcy Protections for Corporations?
The centerpiece of this transformation is *Harrington v. Purdue Pharma*, which rejected what legal professionals call “third-party releases”—provisions that allowed a bankrupt company’s reorganization plan to wipe out claims against non-debtor parties (executives, parent companies, or related entities) even if those parties had never filed for bankruptcy themselves. Before this ruling, companies could use Chapter 11 as a shield: the debtor company would file for bankruptcy, propose a plan that discharged claims against all the real culprits, and claimants would have little choice but to accept whatever settlement was offered because they faced the prospect of getting nothing if the bankruptcy failed. *Harrington* put a hard stop to this practice by requiring that any plan discharging non-debtor liabilities must obtain the affected claimants’ affirmative consent—not just approval by a creditor class, but actual agreement from those being harmed. The impact has been immediate and concrete. In *Purdue Pharma* itself, the bankruptcy court had to restructure its plan twice to comply with the new ruling.
The revised plan that emerged in late 2025 featured $7 billion in direct Sackler family contributions and the creation of a public-benefit company successor, but it narrowed protections for the Sacklers themselves and required far greater involvement and agreement from state attorneys general and claimant representatives. Compare this to the original plan, which would have granted the Sacklers broad releases from future litigation—effectively letting them walk away from opioid litigation with limited exposure. The new approach is more equitable in principle but far more cumbersome in practice, and it has discouraged other solvent corporations from attempting the same strategy. A second important Supreme Court decision, *Truck Insurance Exchange v. Kaiser Gypsum Co.* (2024), expanded who gets a seat at the table in bankruptcy proceedings. The Court held that insurance companies with financial responsibility for mass tort claims qualify as “parties in interest” under bankruptcy law, meaning they can now participate in Chapter 11 plan confirmation hearings and challenge unfavorable settlement terms. This seemingly technical ruling has major consequences: it gives insurers direct leverage to negotiate better terms, which can shift the balance of power away from plaintiffs’ attorneys and toward the insurers footing the bill.
What Happens When Solvent Companies Try to Use Bankruptcy as a Defensive Shield?
One of the clearest signals that the bankruptcy landscape has shifted comes from the Johnson & Johnson talc litigation saga. In 2025, J&J attempted to file its third talc-related Chapter 11 bankruptcy, apparently hoping to create a forum where talc claimants could be channeled into a trust and limited to a fixed settlement pool. The U.S. Bankruptcy Court for the Southern District of Texas rejected the filing outright, effectively barring J&J from using bankruptcy as a forum at all. This was not a subtle message: federal judges now view bankruptcy-shopping by solvent companies as an abuse of process, particularly when the company is trying to use Chapter 11 primarily to escape litigation rather than to genuinely reorganize operations. The limitation here is important: companies that face genuine insolvency and need bankruptcy to survive still retain that option, but the bankruptcy courts have become far more skeptical of filings that appear pretextual.
A solvent company with cash on hand cannot credibly argue that it needs Chapter 11 protection—it can simply pay settlements in the ordinary course of business. J&J’s dismissal signals that courts will scrutinize the timing, substance, and motives behind bankruptcy filings, making this strategy available only to corporations facing true financial distress. For mass tort defendants, this closes off a key playbook and forces them to negotiate openly rather than behind the protective veil of bankruptcy court. This shift also affects the timing and structure of settlement negotiations. Before these rulings, a defendant could file bankruptcy, file a plan, and force claimants to choose between accepting the plan’s terms or risking total loss. Now, without the ability to impose non-debtor releases or to shield executives from liability, defendants have much less leverage in negotiations. They must offer genuinely attractive settlement terms to convince claimants to abandon their right to sue individual perpetrators—and even then, they may not succeed.
What New Mass Torts Are Emerging in 2026?
The bankruptcy rulings of 2024–2026 have coincided with a wave of new and expanding mass tort claims that bankruptcy courts will need to confront in the coming years. Talcum powder litigation (beyond J&J) continues to generate claims against other manufacturers; PFAS (per- and polyfluoroalkyl substances) contamination is spawning claims against chemical manufacturers and water companies; GLP-1 drugs (like Ozempic) used off-label are beginning to produce injury claims; and hernia mesh failures remain a source of ongoing litigation. Each of these involves thousands or tens of thousands of claimants and potential exposure in the billions of dollars. The challenge these mass torts present is that they emerged after *Harrington*, meaning there is no template for bankruptcy resolution in the same way there was for the opioid crisis. When talc claims continue to accumulate against J&J, the company cannot simply file bankruptcy and impose a settlement cap—it must negotiate with claimants or face ongoing litigation.
This shifts leverage substantially toward plaintiffs’ lawyers and away from defendants. For the chemical industry facing PFAS liability, the implications are even more stark: PFAS is a category-wide problem affecting multiple manufacturers, which means that no single bankruptcy will resolve the issue. Instead, the industry faces the prospect of negotiated settlements, MDL proceedings, and potentially hundreds of individual trials. For claimants, this is both a benefit and a risk. The benefit is that they retain leverage to demand better settlements and to pursue appeals or trials if they believe they are entitled to more. The risk is that without a global bankruptcy resolution, some claimants may face individual statutes of limitation or may settle prematurely before the full scope of harm is known.
How Are Courts Redirecting Mass Tort Claims Away from Bankruptcy?
In the wake of *Harrington* and the broader anti-bankruptcy-shopping sentiment, courts and policymakers have begun steering mass tort claims into alternative forums: class actions, multi-district litigation (MDL), and negotiated settlements outside bankruptcy. The Federal Judicial Center and state courts have become more active in consolidating related claims into MDLs, which allow for coordinated discovery and settlement negotiations without the finality and third-party release provisions that bankruptcy enables. For plaintiffs, MDL offers a better deal: multiple judges, juries in different venues, and the ability to pursue individual claims or class certifications without being forced into a bankruptcy trust with a fixed cap. The practical effect is that mass tort litigation is becoming more adversarial and jury-driven. Defendants cannot rely on bankruptcy court judges to craft compromises; instead, they must persuade juries and negotiate with plaintiffs’ committees.
This increases litigation costs and delays for defendants but increases recovery potential for claimants. One tradeoff is that without global bankruptcy resolutions, some claimants may receive substantially more than others depending on where their case is tried and who their attorney is—creating the same unequal treatment that class actions and MDLs are theoretically meant to prevent. The redirect also affects smaller defendants and regional companies. A major pharmaceutical firm facing nationwide talc claims can likely manage multiple MDL proceedings and negotiate favorable settlements because it has resources and scale. A smaller chemical company, by contrast, may face bankruptcy pressure from accumulated PFAS liability even if it is technically solvent. This creates a risk of defendants who cannot afford extended litigation settling prematurely or filing bankruptcy when they might otherwise have survived.
What Legislative Reforms Are Anticipated?
As bankruptcy courts confront emerging mass torts like PFAS and GLP-1 drug claims, calls are intensifying for amendments to Section 524(g) of the Bankruptcy Code, which currently governs how mass tort trusts are established in bankruptcy. Section 524(g) has become the statutory anchor for large bankruptcy settlements, but it was drafted in the context of asbestos litigation and does not adequately address the unique features of modern mass torts. For example, it does not provide clear guidance on how to handle latent injury claims (cases where harm appears years after exposure), how to fund trusts for emerging dangers, or how to balance the interests of present and future claimants. The limitation of the current statutory framework is that any amendment must navigate intense political and litigation pressure. Defendants want broader protections and the ability to cap liability; claimants’ attorneys want higher settlement pools and stronger individual rights; and insurers want clarity on their obligations.
Reaching legislative consensus in this environment is difficult, which means that even if Congress moves to reform Section 524(g), the process could take years. In the interim, bankruptcy courts are left to improvise, creating uncertainty for all parties. A secondary issue is that legislative reform could cut both ways. Congress could strengthen claimants’ rights and restrict bankruptcy filings (aligning with the *Harrington* decision), or it could attempt to make bankruptcy more attractive to defendants as a way to achieve global settlements (rolling back *Harrington*). The outcome will depend on which stakeholder group has more political influence.
How Did the Bad Faith Ruling of June 2026 Further Restrict Bankruptcy Plans?
In June 2026, a federal bankruptcy court in Colorado held that a Chapter 11 plan was unconfirmable because the debtor had proposed it in bad faith. Specifically, the debtor had sought to abridge statutory protections that a tenant held under a rejected lease—in other words, the debtor wanted to use the bankruptcy process to strip away rights that the law guaranteed to the other party. The court refused confirmation, ruling that a plan proposed in bad faith, even if it technically satisfied the statutory requirements for confirmation, should be rejected.
This ruling adds a good-faith requirement to the *Harrington* decision. Even if a plan does not contain non-debtor third-party releases, it can still be rejected if it appears designed to chisel away at statutory protections that Congress intended to preserve. For mass tort defendants, this is a warning: bankruptcy courts will examine the substance of proposed plans, not just their technical compliance with the code. A plan that cuts claimants’ statutory rights (for example, by attempting to deny them the right to participate in trust distributions or to pursue individual claims within statutory limits) can be rejected on bad-faith grounds alone.
What Does the Purdue Pharma Template Mean for Future Mass Tort Bankruptcies?
The revised *Purdue Pharma* plan approved in late 2025 is expected to serve as a template for future mass tort bankruptcies in 2026 and beyond. The key features of this template are: (1) direct family or shareholder contributions in addition to debtor assets; (2) narrowed non-debtor protections, requiring extensive negotiation with state attorneys general and claimant representatives; (3) a public-benefit successor company structure that maintains some operational continuity while submitting to governance oversight; and (4) lower overall settlement caps, reflecting the court’s rejection of the original plan’s expansive releases. For defendants facing large mass tort exposure, this template suggests that bankruptcy will yield smaller settlements and less protection than in the pre-*Harrington* era.
The incentive to file bankruptcy is correspondingly lower, which is consistent with the broader trend of steering mass torts away from bankruptcy and toward MDL and negotiated settlement. However, for companies in true financial distress—those losing money quarter after quarter and facing imminent insolvency—bankruptcy remains an option. The Purdue template shows that even in bankruptcy, they will not receive the sweeping protections and low settlement obligations that earlier bankrupt defendants enjoyed. The financial contribution required from controlling shareholders or insiders is now standard, reflecting the courts’ determination that the wealthiest parties should bear the largest share of the liability.
Frequently Asked Questions
Can a solvent company still file bankruptcy to settle mass tort claims?
A solvent company faces significant judicial skepticism. The 2025 dismissal of Johnson & Johnson’s third talc bankruptcy signals that courts view such filings as pretextual and will reject them. Bankruptcy is available only to companies facing genuine insolvency.
What is a “third-party release” and why did the Supreme Court ban it?
A third-party release is a provision in a bankruptcy plan that discharges claims against non-debtors (like executives or parent companies) without their consent. *Harrington v. Purdue Pharma* (2024) banned this practice because it allowed defendants to escape liability without the agreement of harmed claimants.
How does the revised *Purdue Pharma* plan differ from the original?
The revised plan (late 2025) features approximately $7 billion in Sackler family contributions and significantly narrowed protections for non-debtors. The original plan would have granted the Sacklers broad releases from future litigation. The new plan required extensive negotiation with state attorneys general and claimant representatives.
What alternative forums are mass tort claims moving into?
Multi-district litigation (MDL), class actions, and negotiated settlements outside bankruptcy are now the primary venues for mass tort resolution. These forums allow claimants to retain leverage and pursue individual claims or class certifications without being forced into a bankruptcy trust with a fixed cap.
What emerging mass torts are likely to reshape the bankruptcy landscape in 2026?
Talcum powder (beyond J&J), PFAS contamination, GLP-1 drug injuries, and hernia mesh failures are generating thousands of claims and potential exposure in the billions of dollars. Unlike opioids, these torts emerged after *Harrington*, so there is no bankruptcy template for resolving them.
Are there proposals to reform bankruptcy law for mass torts?
Yes, calls are intensifying for amendments to Section 524(g) of the Bankruptcy Code to address emerging mass torts and improve clarity on trust funding and claimant protections. However, legislative reform remains uncertain and could take years.